SCHEMBL13145643

SCHEMBL13145643

CC(C)(C)c1ccc(F)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.53
CES2 O00748 2/20 0.44
CES1 P23141 2/20 0.44
GLRA3 O75311 1/20 0.41
GLRB P48167 1/20 0.41
RBP4 P02753 2/20 0.40
NOTUM Q6P988 2/20 0.40
DHODH Q02127 2/20 0.40
MPO P05164 1/20 0.40
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
KCNN4 O15554 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
DHFR P00374 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL455239 0.86 KEAP1 (0.50) KEAP1CES2CES1GLRA3GLRB
SCHEMBL27661023 0.85 KEAP1 (0.55) KEAP1CES2CES1NOTUMDHODH
SCHEMBL12251320 0.85 NPC1 (0.44) KEAP1CES2CES1ALDH1A1KCNN4
SCHEMBL222474 0.82 KEAP1 (0.55) KEAP1CES2CES1RBP4NOTUM
SCHEMBL29406303 0.82 KEAP1 (0.55) KEAP1CES2CES1RBP4NOTUM
SCHEMBL16953726 0.80 PTGS1 (0.41) KEAP1CES2CES1KDM4EALDH1A1
SCHEMBL5873299 0.78 TDP1 (0.57) CES2GLRA3GLRBNOTUMALDH1A1
SCHEMBL4238024 0.78 CSNK2A1 (0.57) GLRA3GLRBNOTUMKDM4EALDH1A1
SCHEMBL1355563 0.78 RARB (0.49) GLRA3GLRBKDM4EMEN1CA1
SCHEMBL19665480 0.78 CA12 (0.55) GLRA3GLRBALDH1A1HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170240586-A1 Benzoic Acid Derivatives of Bile Acid as FXR/TGR5 Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-08-24 US disclosed
US-20170240586-A1 Benzoic Acid Derivatives of Bile Acid as FXR/TGR5 Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-08-24 US disclosed
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CCR2, CCR9, CCR1 KEAP1 821/4885CES2 485/4885CES1 423/4885
US-20170240586-A1 Benzoic Acid Derivatives of Bile Acid as FXR/TGR5 Agonists and Methods of Use Thereof GPBAR1, NR1H4, SLC10A1 KEAP1 1206/4885CES2 1057/4885CES1 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.